[English]  [Pусский]  [中文]  
ctt-journal > Shats et al. (Abstract)

Shats et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract32
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment


Positron emission tomography (PET) for the evaluation of pediatric brain tumors

Ludmila I. Shats1,2, Galina G. Radulesku1,2, Tatiana D. Victorovich1,2, Emilia D. Chavpezova1, Anna S. Haritonova2, Julia V. Dinikina2, Margarita B. Belogurova1,2

1City clinical hospital No.31, Department of pediatric oncology & hematology, Saint-Petersburg, Russia; 2SPbGPMA, Division of oncology with course of radiology diagnostic and treatment, Saint-Petersburg, Russia

Correspondence: Ludmila I. Shats, City clinical hospital №31, 3, Dinamo, Saint-Petersburg, 197110, Russia, E-mail: deton.hospita31@spam is badinbox.ru


Background: Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain neoplasm.

Method: A retrospective clinical and radiological review of data in patients with brain tumors treated in the Department of Pediatric Oncology of City Hospital No. 31, St. Petersburg, between 2000 and 2009.

Results: Forty-one MET-PET scans from 21 patients (10 male and 11 female) aged from 2 to 21 years (median of age 7 years) were analyzed. Tumors included were: low grade glioma (2pts), high-grade glioma (9 pts), anaplastic ependymoma (1 pt), medulloblastoma (2 pts), cerebral neuroblastoma (1 pt), ATRT (2 pts), and diffuse brainstem tumor 4 (pts). The median follow-up time was 30 months. In 2 patients with brainstem tumors, PET was provided before treatment. In 2 patients PET was done after surgery to assess the extension of brain tumor resection. In all patients PET was a tool in the monitoring during and after a treatment.

Metabolic characteristics were assessed with MET standardized uptake values (SUV). In our group the SUV was 1.1–4.4. In two patients with malignant tumors (anaplastic ependymoma and medulloblastoma) the SUV was 1.1 and 1.2. In one patient with glioblastoma after radio- and chemotherapy, MET-PET was used successfully to differentiate radionecrosis from tumor recurrence.

Conclusions: Differentiation between malignant lesions and low grade tumors is not always possible. MET-PET is a tool in the detection of tumor recurrence, malignant degeneration, and radiation reaction. The survival time was significantly longer in patients with negative PET during and at the end of treatment.

Keywords: PET, methionine, pediatric brain tumors


<-- Previous abstract        Contents        Next abstract -->

Contribute a comment